Literature DB >> 2180049

Anaemia in rheumatoid arthritis: pathogenesis, diagnosis and treatment.

G Vreugdenhil1, A J Swaak.   

Abstract

The pathogenesis, diagnosis and treatment of the anaemia of chronic disorders (ACD) in rheumatoid arthritis (RA) were reviewed. Causes of anaemia other than ACD frequently present in RA. Decreased iron absorption was shown to be the result of active RA rather than a cause of ACD or iron deficiency. It has been hypothesized that bone marrow iron availability decreases due to decreased iron release by the mononuclear phagocyte system or that the anaemia in ACD is due to ineffective erythropoiesis; these remain controversial theories. Studies considering a decreased erythropoietin responsiveness have not produced consistent results. Erythroid colony growth is suppressed in vitro by interleukins and tumour necrosis factor but their role in vivo in ACD is unknown. The diagnosis of ACD is made by exclusion. Iron deficiency is detected by transferrin, ferritin, and cellular indices after adaptation of their normal values. Treatment of the anaemia consists merely of antirheumatic treatment. Iron administration is counterproductive since iron chelators or exogenous erythropoietin administration might increase erythropoiesis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2180049     DOI: 10.1007/BF00541320

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  161 in total

1.  THE DIAGNOSIS OF IRON DEFICIENCY ANEMIA.

Authors:  D F BAINTON; C A FINCH
Journal:  Am J Med       Date:  1964-07       Impact factor: 4.965

2.  SIDEROBLASTIC ANAEMIA IN MAN: OBSERVATIONS ON SEVENTY CASES.

Authors:  B H MACGIBBON; D L MOLLIN
Journal:  Br J Haematol       Date:  1965-01       Impact factor: 6.998

3.  Normal response to erythropoietin or hypoxia in rats made anemic with turpentine abscess.

Authors:  A GUTNISKY; D VAN DYKE
Journal:  Proc Soc Exp Biol Med       Date:  1963-01

4.  Characteristics of iron dextran utilization in man.

Authors:  P A Henderson; R S Hillman
Journal:  Blood       Date:  1969-09       Impact factor: 22.113

5.  Serum levels of interleukin-6 and acute phase responses.

Authors:  M W Nijsten; E R de Groot; H J ten Duis; H J Klasen; C E Hack; L A Aarden
Journal:  Lancet       Date:  1987-10-17       Impact factor: 79.321

6.  Haem biosynthesis in rheumatoid disease.

Authors:  B C Campbell; N Rennie; G G Thompson; M R Moore; A Goldberg
Journal:  Br J Haematol       Date:  1978-12       Impact factor: 6.998

7.  Decreased interleukin 2 inhibitor in sera of patients with autoimmune disorders.

Authors:  J Y Djeu; T Kasahara; J E Balow; G C Tsokos
Journal:  Clin Exp Immunol       Date:  1986-08       Impact factor: 4.330

8.  Treatment of rheumatoid arthritis with desferrioxamine.

Authors:  R J Polson; A S Jawad; A Bomford; H Berry; R Williams
Journal:  Q J Med       Date:  1986-12

9.  Stimulating spectrum of human recombinant multi-CSF (IL-3) on human marrow precursors: importance of accessory cells.

Authors:  F J Bot; L Dorssers; G Wagemaker; B Löwenberg
Journal:  Blood       Date:  1988-06       Impact factor: 22.113

Review 10.  Characterization of a leukocyte-derived endogenous mediator responsible for increased plasma fibrinogen.

Authors:  R F Kampschmidt; H F Upchurch; L A Pulliam
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

View more
  8 in total

1.  Structured approach to the investigation of anaemia in patients with rheumatoid arthritis.

Authors:  A Doube; M Davis; J G Smith; P J Maddison; A J Collins
Journal:  Ann Rheum Dis       Date:  1992-04       Impact factor: 19.103

2.  Effects of intravenous iron saccharate on improving severe anemia in rheumatoid arthritis patients.

Authors:  Wei-Sheng Chen; Chun-Yu Liu; Hui-Ting Lee; Kelvin Tsai; Yi-Chun Lin; Der-Cherng Tarng; Chao-Hung Ho; Hsiao-Yi Lin
Journal:  Clin Rheumatol       Date:  2011-10-29       Impact factor: 2.980

Review 3.  Interaction of inflammatory cytokines and erythropoeitin in iron metabolism and erythropoiesis in anaemia of chronic disease.

Authors:  M Jongen-Lavrencic; H R Peeters; G Vreugdenhil; A J Swaak
Journal:  Clin Rheumatol       Date:  1995-09       Impact factor: 2.980

4.  Ratio of baseline erythropoietin (EPO) level and corrected reticulocyte count as an indicator for a favourable response to recombinant human erythropoietin (rhEPO) therapy in anaemic cancer patients.

Authors:  N Charuruks; N Voravud; W Limpanasithikul
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

5.  Correlation of interleukin-2 receptor and neopterin secretion in rheumatoid arthritis.

Authors:  W Kullich
Journal:  Clin Rheumatol       Date:  1993-09       Impact factor: 2.980

6.  Iron stores and serum transferrin receptor levels during recombinant human erythropoietin treatment of anemia in rheumatoid arthritis.

Authors:  G Vreugdenhil; B Manger; C Nieuwenhuizen; R A Feelders; H G van Eijk; A J Swaak
Journal:  Ann Hematol       Date:  1992-12       Impact factor: 3.673

7.  Transferrin microheterogeneity in rheumatoid arthritis. Relation with disease activity and anemia of chronic disease.

Authors:  R A Feelders; G Vreugdenhil; G de Jong; A J Swaak; H G van Eijk
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

Review 8.  A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.

Authors:  Thomas Bieber; Eugen Feist; Alan D Irvine; Masayoshi Harigai; Ewa Haladyj; Susan Ball; Walter Deberdt; Maher Issa; Susanne Grond; Peter C Taylor
Journal:  Adv Ther       Date:  2022-09-05       Impact factor: 4.070

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.